Similar Papers

Paper Title
Journal
Date
Author
A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
John Grainger ... Bhakti Mehta
Blood | VOL. 128
John Grainger, et. al.John Grainger ... Bhakti Mehta
02 Dec 2016
Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
Michael Tarantino ... Melissa Eisen
Blood | VOL. 130
Michael Tarantino, et. al.Michael Tarantino ... Melissa Eisen
25 Jun 2021
Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year
David J Kuter ... Melissa Eisen
Blood | VOL. 130
David J Kuter, et. al.David J Kuter ... Melissa Eisen
25 Jun 2021
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
David J Kuter ... Nichola Cooper
Blood | VOL. 134
David J Kuter, et. al.David J Kuter ... Nichola Cooper
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.